MSH2 alterations were also seen in four patients in the GIST cohort, four in the uterine sarcoma cohort – three leiomyosarcomas and one adenosarcoma – and two in the bone sarcoma cohort (conventional type chordoma and chondrosarcoma). This evidence concerns the gene MSH2 and uterine corpus sarcoma.